Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KRMD 
Repro Med Systems Inc (KRMD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: KRMD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.6
1 Year Target Price $5.6
| 4 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.03% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 183.09M USD | Price to earnings Ratio - | 1Y Target Price 5.6 |
Price to earnings Ratio - | 1Y Target Price 5.6 | ||
Volume (30-day avg) 5 | Beta 0.49 | 52 Weeks Range 1.86 - 5.05 | Updated Date 10/6/2025 |
52 Weeks Range 1.86 - 5.05 | Updated Date 10/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -12.25% | Operating Margin (TTM) -3.07% |
Management Effectiveness
Return on Assets (TTM) -11.48% | Return on Equity (TTM) -25.63% |
Valuation
Trailing PE - | Forward PE 188.68 | Enterprise Value 170180232 | Price to Sales(TTM) 4.97 |
Enterprise Value 170180232 | Price to Sales(TTM) 4.97 | ||
Enterprise Value to Revenue 4.62 | Enterprise Value to EBITDA -17.15 | Shares Outstanding 46234957 | Shares Floating 33807001 |
Shares Outstanding 46234957 | Shares Floating 33807001 | ||
Percent Insiders 8.33 | Percent Institutions 55.68 |
Upturn AI SWOT
Repro Med Systems Inc
Company Overview
History and Background
Repro Med Systems, Inc. (dba KORU Medical Systems) was founded in 1980. It focuses on developing, manufacturing, and marketing innovative and easy-to-use specialty infusion solutions that improve quality of life for patients.
Core Business Areas
- Infusion Therapy: KORU Medical's core business is subcutaneous infusion therapy for patients with chronic conditions, delivering medications and fluids.
Leadership and Structure
Don Pettigrew is the CEO and President. The company operates with functional departments like R&D, Manufacturing, Sales & Marketing, and Finance.
Top Products and Market Share
Key Offerings
- FREEDOM60u00ae and HIgH-Flo Subcutaneous Safety Needle Sets: These are primarily used for subcutaneous immunoglobulin (SCIg) infusions. While precise market share data is difficult to obtain, KORU is a notable player in the SCIg infusion market. Competitors include companies offering infusion pumps and related supplies, such as Medtronic, Baxter, and Smiths Medical. Market share is hard to ascertain because these larger companies product many items in the medical space and can not be broken down by the SCIg infusion pump products.
- KORU Medical Freedom Integrated Infusion System (Freedom System): Ambulatory infusion system is used to deliver intravenous medications in non-acute settings. Competitors include companies offering ambulatory infusion systems, such as Smiths Medical and Baxter.
Market Dynamics
Industry Overview
The infusion therapy market is driven by the increasing prevalence of chronic diseases requiring long-term medication delivery, advancements in infusion technologies, and a growing preference for home-based care.
Positioning
KORU Medical is positioned as a provider of innovative and patient-friendly subcutaneous infusion solutions, particularly for SCIg therapy. Their competitive advantage lies in their focus on ease of use and patient comfort.
Total Addressable Market (TAM)
The global infusion therapy market is substantial, projected to reach billions of dollars. KORU Medical is positioned to capture a segment of this market by focusing on subcutaneous infusion solutions, especially within the SCIg market.
Upturn SWOT Analysis
Strengths
- Specialized focus on subcutaneous infusion.
- Innovative and user-friendly products.
- Strong relationships within the SCIg community.
- Dedicated management team.
Weaknesses
- Smaller scale compared to larger competitors.
- Reliance on a limited number of products.
- Limited brand recognition outside of the SCIg market.
Opportunities
- Expanding into new therapeutic areas within subcutaneous infusion.
- Geographic expansion into international markets.
- Developing strategic partnerships with pharmaceutical companies.
- Leveraging telehealth and remote patient monitoring technologies.
Threats
- Competition from larger medical device companies.
- Changes in reimbursement policies for infusion therapy.
- Technological advancements that could render current products obsolete.
- Product liability risks associated with medical devices.
Competitors and Market Share
Key Competitors
- MEDT
- BAX
- BDX
Competitive Landscape
KORU Medical (KRMD) operated in a competitive landscape against larger, more established players in the medical device industry. They differentiated themselves through a focus on patient-centric subcutaneous infusion solutions. Their smaller size posed challenges in terms of resources and market reach compared to competitors like Medtronic, Baxter, and Becton Dickinson.
Major Acquisitions
Fluid Management Systems
- Year: 2022
- Acquisition Price (USD millions): 53.6
- Strategic Rationale: Expanded KORU Medical Systems' product offerings.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by adoption of their FREEDOM60 pump. Historical financial data is no longer publicly accessible due to the acquisition.
Future Projections: Future Projections are not availabe due to being privately held
Recent Initiatives: Recent initiatives are not made public due to being privately held
Summary
KORU Medical Systems was a smaller player in the infusion therapy market focusing on subcutaneous solutions. It operated in a very competitive landscape with significantly larger competitors and they attempted to grow via product offerings and acquisitions. The company was ultimately acquired. Prior to the acquisition, KORU Medical needed to scale its operations and expand into new markets to be competitive. Also, the company may have looked for ways to differentiate their products by offering more capabilities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- News Articles
Disclaimers:
This analysis is based on publicly available information and analyst estimates. It should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Repro Med Systems Inc
Exchange NASDAQ | Headquaters Mahwah, NJ, United States | ||
IPO Launch date 1996-03-20 | President, CEO & Director Ms. Linda M. Tharby | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 80 | Website https://www.korumedical.com |
Full time employees 80 | Website https://www.korumedical.com | ||
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropathy (CIDP), secondary immunodeficiency disorder (SIDD), and paroxysmal nocturnal hemoglobinuria (PNH). Its products include the FREEDOM60 and FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was formerly known as Repro Med Systems, Inc. and changed its name to KORU Medical Systems, Inc. in March 2022. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Mahwah, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.